New considerations in antiviral therapy for special populations with chronic hepatitis B / 临床肝胆病杂志

ABSTRACT

Increasing attentions have been paid to the antiviral therapy for special populations with chronic hepatitis B (CHB), including patients co-infected with HIV, HDV, or HCV, children and adolescents, pregnant women, patients with chronic kidney diseases, and patients who require chemotherapy or immunosuppressive therapy. The indications for antiviral therapy, drug selection and adjustment, and treatment course in special populations with CHB have become the hot topics of clinical research. In recent years, all guidelines for the prevention and treatment of CHB have provided a summary of key considerations in the standardized management of these populations. However, the strength of recommendations for antiviral therapy in these populations is not high. In order to obtain a strong medical evidence for antiviral therapy in these populations, we should standardize clinical management processes and carry out high-quality cohort studies based on the previous research.